Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised …
…, V Goranova-Marinova, A Schwarer, L Minuk… - The Lancet …, 2016 - thelancet.com
Background Bortezomib with dexamethasone is a standard treatment option for relapsed or
refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity …
refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity …
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
…, R Hajek, K Weisel, V Hungria, L Minuk… - The Lancet …, 2017 - thelancet.com
Background The phase 3 ENDEAVOR trial was a head-to-head comparison of two
proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free …
proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free …
[HTML][HTML] Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus …
M Delforge, L Minuk, JC Eisenmann, B Arnulf… - …, 2015 - ncbi.nlm.nih.gov
We compared the health-related quality-of-life of patients with newly diagnosed multiple
myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients …
myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients …
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open …
…, A Grigg, B De Prijck, M Louzada, L Minuk… - The Lancet …, 2022 - thelancet.com
Background Elotuzumab plus lenalidomide and dexamethasone has shown improved
progression-free and overall survival versus lenalidomide and dexamethasone in patients with …
progression-free and overall survival versus lenalidomide and dexamethasone in patients with …
[PDF][PDF] Decreased hepatocyte membrane potential differences and GABAa‐β3 expression in human hepatocellular carcinoma
To determine whether hepatocyte membrane potential differences (PDs) are depolarized in
human HCC and whether depolarization is associated with changes in GABA A receptor …
human HCC and whether depolarization is associated with changes in GABA A receptor …
Desmopressin responsiveness at a capped dose of 15 μg in type 1 von Willebrand disease and mild hemophilia A
…, L Laudenbach, S Schembri, L Minuk - Blood Coagulation & …, 2014 - journals.lww.com
Desmopressin (DDAVP) is commonly used in the treatment of patients with type 1 von
Willebrand disease (VWD) and mild hemophilia A. A patient's responsiveness to DDAVP based …
Willebrand disease (VWD) and mild hemophilia A. A patient's responsiveness to DDAVP based …
[HTML][HTML] Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
SC Jackson, M Yang, L Minuk, M Sholzberg, J St-Louis… - BMC hematology, 2015 - Springer
Background Although prophylaxis is a standard of care for young children in developed
countries, known to reduce the severity of hemophilic arthropathy, older adults with existing …
countries, known to reduce the severity of hemophilic arthropathy, older adults with existing …
[HTML][HTML] Normal levels of protein C and protein S tested in the acute phase of a venous thromboembolic event are not falsely elevated
L Minuk, A Lazo-Langner, J Kovacs, M Robbins… - Thrombosis …, 2010 - Springer
Background Protein C (PC) and protein S (PS) determination is part of the thrombophilia
investigation in patients with idiopathic venous thromboembolism (VTE). Based on scarce …
investigation in patients with idiopathic venous thromboembolism (VTE). Based on scarce …
Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not …
LA Minuk, K Monkman, IH Chin-Yee… - Leukemia & …, 2012 - Taylor & Francis
Although patients with Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine
and dacarbazine (ABVD) chemotherapy frequently develop neutropenia, febrile neutropenia …
and dacarbazine (ABVD) chemotherapy frequently develop neutropenia, febrile neutropenia …
The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies
…, A Lazo-Langner, BH Chin-Yee, LA Minuk - Leukemia & …, 2011 - Taylor & Francis
Patients with hematological malignancies are at increased risk of influenza and its complications,
but evidence for the efficacy of influenza vaccination in this population is limited. We …
but evidence for the efficacy of influenza vaccination in this population is limited. We …